Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAB-185 in Healthy Subjects
NCT04468958Phase 1Completed
- Sponsor
- SAB BIO
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAB-185 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by SAB BIO. Primary endpoints: Number of Participants Having Adverse Events at 29 Days and Number of Participants Having Transfusion-Related Adverse Events at 29 Days. Started Jul 2020; status: completed.
02
Drugs
SAB-185
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04468958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468958.